Photo of Prof. Zeev Rotstein, head of Hadassah-University Medical Center, being screened for eligibility to be vaccinated on Monday as part of the Phase II trial of the Israeli vaccine candidate Brilife. December 20, 2020 (photo credit: HADASSAH)
{}